Incara starts Phase II/III with OP2000

INCR began a U.S. Phase II/III trial of OP2000, a subcutaneous ultra-low molecular weight heparin, to treat ulcerative colitis. The placebo-controlled trial will enroll 270 patients with active ulcera...